Part B of the phase 2 APEX trial evaluated three zumilokibart dosing regimens in adults with moderate-to-severe atopic dermatitis. All three met the primary endpoint at Week 16, with findings supporting mid dose selection for phase 3. Dr Melinda Gooderham discusses the efficacy and safety results from both Part A and Part B and what they could mean for clinical practice and those living with AD.
Could abdakibart offer a new treatment option for hidradenitis suppurativa? Dr Martina L. Porter discusses encouraging findings from the phase 2 LOTUS trial, including improvements in disease severity and draining tunnels, alongside a reassuring safety profile over 16 weeks, and considers what these results could mean for clinical practice.
For women taking dupilumab to manage atopic dermatitis or asthma, limited pregnancy safety data can make treatment decisions challenging. Dr Christina Chambers discusses reassuring findings from a registry study of 539 pregnancies and how they could help clinicians counsel women who are pregnant or planning a family.
Encouraging findings from JAKPPPOT support the feasibility of a definitive randomized controlled trial of Janus kinase inhibitors in palmoplantar pustulosis and provide an exploratory estimate of treatment effect. We spoke with Dr David Gleeson about the results presented at EADV 2026 and their implications for future research.
RLS-1496 1% cream is an investigational senotherapeutic treatment that inhibits GPX4. It aims to target senescent cells, potentially offering a new approach to treating actinic keratosis (AK). Encouraging findings from a phase 1b/2a, multicenter, open-label study were presented at EADV 2026. We spoke with Dr Mary Spellman, who presented the findings, about the results and their implications for the treatment’s future development.
Drug repurposing could offer new treatment opportunities for rare genetic skin diseases. Prof. Dédée Murrell discusses the rationale for exploring existing medicines, progress in epidermolysis bullosa, and how a new trial aims to match treatments to patients’ inflammatory profiles rather than their genetic subtype.
Sonelokimab showed encouraging results in the phase 2 LEDA trial in adults with palmoplantar pustulosis. Dr Nina Magnolo discusses the findings, including a mean 64% reduction in disease severity at Week 16, and their potential implications for patients.
How does bimekizumab perform in everyday clinical practice? An Italian multicenter study reported improvements in disease activity, pain, and quality of life in people with hidradenitis suppurativa, with no unexpected safety signals. Dr Mario Valenti shares the findings and his perspective with touchDERMATOLOGY.
On Day 2 of the EADV 2026 congress, we were delighted to speak with touchDERMATOLOGY Editorial Board member, Dr Maria Angeliki Gkini who shared her highlights from key psoriasis sessions and discussed what these developments could mean for clinical practice.
What did the Women’s Dermatologic Society bring to EADV 2026? Explore session highlights spanning blistering diseases, skin cancer, scarring alopecias, and more. Prof. Dedee Murrell introduces the society’s focus on mentorship, explains why the session is worth watching, and shares why dermatologists should consider joining.
New 52-week REZOLVE-AD data showed durable responses with monthly and quarterly rezpegaldesleukin (REZPEG) maintenance dosing in atopic dermatitis. Prof. Thomas Bieber discusses the findings and the potential for long-term remission and disease modification, highlighting the further evidence needed to explore these goals.
What were the key dermatology updates at EADV 2026? Dr Melinda Gooderham shares her highlights, exploring the Janus kinase (JAK) inhibitors session, new data comparing zasocitinib with deucravacitinib, and 2-year findings from ICONIC-TOTAL evaluating icotrokinra.
Could glucagon-like peptide-1 receptor agonists affect nail health? A multinational study presented at EADV 2026 found nail disorders were reported more frequently among users, with nearly sevenfold higher odds of nail detachment. Prof. Bianca Maria Piraccini discusses the findings and why further clinical assessment is needed.
Through our new collaboration, we will work together to increase the visibility of important developments in dermatology, from the latest clinical research and scientific advances to key society news and updates. As part of the partnership, touchDERMATOLOGY will also bring our community independent coverage directly from the EADV Congress, including the latest data, expert perspectives, key clinical takeaways and onsite interviews with leading specialists.
With EADV Congress 2026 just around the corner, there is plenty to look forward to in Vienna from 30 September to 3 October. If you are joining this year, whether onsite or online, the keynote and plenary sessions are well worth making time for in your congress schedule.
